Organon (2)

Executive Summary

Organon, spun off from Merck in 2021, is a global healthcare company dedicated to improving women's health through a diversified portfolio that includes women's health products, biosimilars, and established brands. Operating in over 140 markets, the company focuses on conditions that uniquely or disproportionately affect women, such as contraception, fertility, and menopause. Despite facing generic competition for some of its key products like Nexplanon, Organon has been investing in its biosimilars pipeline to drive growth. In 2023, it launched its first biosimilar, Hadlima (a biosimilar to Humira), and has several more in development through partnerships with Samsung Bioepis and others. The company's strategy includes expanding access to women's healthcare in emerging markets and leveraging its commercial infrastructure to launch new products. With a valuation of approximately $1.66 billion and 8 commercial products, Organon presents a mixed profile: established revenue streams from legacy products but a need for pipeline success to offset patent losses. The near-term outlook hinges on regulatory approvals for key biosimilars, particularly for Stelara and Xgeva, which could significantly boost earnings. Additionally, the company's focus on women's health provides a unique market position, though it remains a relatively small player compared to larger pharma firms. Overall, Organon's success will depend on execution of its biosimilar launches and its ability to innovate in women's health. The conviction score is moderate given the uncertainty around pipeline timelines and competitive pressures.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on biosimilar to Stelara (ustekinumab, SB17)80% success
• H2 2026Launch of biosimilar to Xgeva/Prolia (denosumab, SB16) in Europe70% success
• TBDPotential partnership or in-licensing of a late-stage women's health asset50% success